Friday, 12 March 2021 09:44

Anticoagulation news items. Week commencing 8th March 2021

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients

EClinical Medicine
Analysis of 607 of 1113 records in Mayo Clinic Electronic Health Record database found that COVID-19 patients administered unfractionated heparin but not enoxaparin had higher rates of 28-day mortality (risk ratio: 4.3; 95% CI; 1.8-10.2).

 

Epistaxis

New England Journal of Medicine
Review covers vasoconstrictors, tranexamic acid, cauterisation, anterior nasal packing, resorbable/non-resorbable packing, salvage bleeding control, posterior packing, ligation & endovascular embolisation, patients on anticoagulant and antiplatelets, and patient education.

 

European PRAC starts review of signal of thrombocytopenia with Pfizer/BioNTech, AstraZeneca and Moderna COVID-19 vaccines

European Medicines Agency
Several cases of immune thrombocytopenia, an adverse event of special interest, were reported in the EudraVigilance database. The PRAC will carry out an in-depth review of all the available data for these three vaccines, to decide if a causal relationship is confirmed or not.

 

World Health Organisation’s global advisory committee on vaccine safety reviewing AstraZeneca Covid-19 vaccine

Reuters Health
A World Health Organization expert advisory committee is currently looking at AstraZeneca's COVID-19 vaccine after some countries suspended its use, following reports of the formation of blood clots in some people who have been vaccinated.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services